Biotechnology

Lux Capital

Check: No personal check-size range is published. Lux invests early and can support companies across their development, but its USD 7B under management and individual financing totals are not Peter's personal allocation limits.

Peter seeks scientifically and technologically ambitious ventures attempting what most people think will not work but could become indispensable if they succeed. He is a generalist across technology and healthcare, with a particular record in multidisciplinary platforms—robotics, software, data, imaging, AI, and biology—that expand human capability, create new categories, and convert substantial technical risk into outsized societal and economic value.

Khosla Ventures

Check: In a 2020 first-person interview, Samir described a typical Khosla Seed Fund investment as roughly $1M–$2M, used as option-value capital to remove key risks before a larger Series A/B decision. Khosla's current Main Fund covers early through later stages, including total financings above $10M. These are historical/firm-level guideposts, not a guaranteed current personal range.

Samir prefers large, known markets where a radical technical risk can produce a 10x-better product. He treats small seed checks as option-value experiments: identify a potential billion-dollar outcome, use capital to remove a binary technical, team, or market-development risk, then redo the diligence and concentrate capital if the evidence improves. He rejects mechanical pro-rata, values non-consensus decisions, and believes uncapped upside justifies bold technical bets rather than conservative hit-rate optimization.

Khosla Ventures

Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.

Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.

Lux Capital

Check: No verified personal or standard Lux check-size range is published. Tess invests at both early and growth stages and participates in Lux company creation; founders should confirm round fit directly rather than infer an allocation from fund size or disclosed company rounds.

Tess is a technically trained generalist investing where AI, biology, aerospace, and the physical world intersect. She seeks engineers and scientists turning frontier research into companies, with particular interest in computational methods that make biology more engineerable, the data and model bottlenecks behind scientific discovery, and high-consequence systems such as biodefense.

Lux Capital

Check: No verified personal or standard Lux check-size range is published. Shahin invests from early conviction through enduring scale and has co-founded companies; financing requirements are opportunity-specific and should be confirmed directly.

Shahin creates and backs generational frontier companies that endow people and machines with new capabilities. An engineer and founder, he looks across AI, chips, compute, autonomy, aerospace, robotics, biotech, defense, energy, and infrastructure for radical underlying technologies—not diminishing improvements—that can unlock previously impossible products. He invests early, may help form companies, and supports founders through technical proof, customer trust, manufacturing, and scale.

Lux Capital

Check: No personal check-size range is published. Lux's USD 7B under management and disclosed company rounds are not Grace's personal range; she is explicitly described as a first-check and early investor.

Grace backs computational-science companies where software or AI transforms difficult physical, institutional, or technical systems. She looks for first-check opportunities in infrastructure and applications, including model platforms, developer tools, generative media, robotics, and AI-native enterprise workflows. Her product lens starts with a painful real-world experience and asks whether new fundamental technology enables an excellent end-to-end product, rather than an AI feature bolted onto an old workflow.

Lux Capital

Check: Lux does not publish a dependable personal check range for Deena. Her investments span stages, including first institutional rounds and later healthcare financings; founders should confirm vehicle, initial ticket, ownership, reserves and stage fit with the partnership.

Deena backs transformative technologies that improve health, access and economic opportunity, often with extraordinary underdog founders attacking problems conventional pattern recognition overlooks. Her health thesis pairs breakthrough science and AI with clinical value, infrastructure and community delivery: technology matters only when it improves outcomes for populations historically underserved by fragmented systems.

Union Square Ventures (USV)

Check: USV states that the firm writes $1 million to $30 million checks and invests from the earliest stages through the full company journey. This is a firm-wide range, not Albert's personal check authority; decisions are discussed collectively without a formal vote.

Albert is a thesis-driven generalist investing at the edge of large markets under technological and societal pressure. His current work emphasizes AI-enabled scientific discovery, robotics that can operate reliably in complex physical environments, resilient energy and civil infrastructure, and products that expand human agency. Across these areas he looks for compounding data or participation loops and systems that turn rapidly improving technical capabilities into durable real-world utility.

Khosla Ventures

Check: No personal check range is published. Khosla's firm-level Seed and Main Funds span technical experiments through later financings; historical seed commentary cited roughly $1M–$2M. Nicole's additional Capital Formation role should not be read as a disclosed personal check authority.

Nicole backs frontier AI across infrastructure, enterprise, consumer, defense, and biology. Her scientific training in cancer and viral immunology gives her a mechanistic lens for AI–biology convergence, while her founder experience provides a capital-efficient consumer and commercialization perspective. Her named investments—Medal/General Intuition, Highlight, Cellular Intelligence, and Vero—signal interest in world models and embodied intelligence, consumer/enterprise software, biological intelligence, and defense applications.

Lux Capital

Check: Not applicable to Nat's events role. Lux invests across stages, but no personal allocation authority or check size belongs to this profile. Founder financing pitches should go to Lux's investment team.

Nat designs the convening layer around Lux's frontier-science and technology network. Her work brings together founders, researchers, executives, investors, journalists and creative leaders in focused formats such as AI, AI-biology and health-intelligence summits. The operating thesis is that carefully curated, content-rich gatherings create trust, knowledge exchange and useful founder connections. It is a platform thesis, not a personal investment thesis.

Kleiner Perkins

Check: No personal or standard firm-wide check range is published. Ilya's official portfolio spans early and growth investments; Kleiner disclosed that its 2019 Series A investment in Rippling was $25M, but that one transaction is not a general range or personal limit.

Ilya invests in technology and novel business models capable of fundamentally reshaping industries. His portfolio connects AI-native professional work, enterprise operating systems, mathematical and software agents, physical AI, autonomous defense, logistics, healthspan, biotech, and financial infrastructure. A recurring pattern is a product-centric company that can redefine a large workflow and pair a technical discontinuity with a new go-to-market or business model.

Big Pi Ventures

Check: Firm-wide: Big Pi publishes €0.5M–€30M equity tickets across early-stage and growth funds; its dedicated Growth I strategy leads €7M–€20M+ investments. The site does not publish Nick's personal range, so stage and fund fit must be confirmed per opportunity.

Nick sees biology and robotics as major technology waves and looks for companies using high-quality real-world data, deep technical capability, and customer evidence to automate tasks previously considered impossible. More broadly, he believes Greece's overlooked engineering and biology talent plus its diaspora can support global companies—provided founders internationalize early, raise their ambition, and pair innovation with business development and scalable operations.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Reinhard Krickl invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Nora Kaarela invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Florian Eckhardt is listed in a Senior Advisor capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Lene Gerlach invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Lene Dragesund is listed in a Senior Office Manager capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Pål R. Jensen is listed in a Senior Advisor Operations capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Silje C. L. Ervik is listed in a Head of Legal capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Vilde Fredheim is listed in a Director, Investor Relations & Business Development capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Paal August Nordhagen is listed in a Director of Finance & Controlling capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Camilla Olsen is listed in a Impact & ESG Manager capacity at Hadean Ventures. The profile preserves that non-investment or undisclosed-role distinction and uses the firm's mandate only as shared context.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Markèta Chlubnovà invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Yun Yang invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Markus Dietrich invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Miao He invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Georgina Askeland invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Roger Franklin invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Walter Stockinger invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

Hadean Ventures

Check: Hadean Ventures does not publish a standard current check-size range on its official website.

Ingrid Teigland Akay invests or supports investment decisions through Hadean Ventures's published strategy: Back science-driven European healthcare companies with the potential to improve patient outcomes and create durable value.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Thomas Videbæk is listed by NOON Ventures as Industrial Advisor. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Thomas Thune Andersen is listed by NOON Ventures as Industrial Advisor. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Odd Hansen is listed by NOON Ventures as Industrial Advisor. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Morten Schaldemose is listed by NOON Ventures as Industrial Advisor. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Henriette Kirkegaard is listed by NOON Ventures as Industrial Advisor. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Flemming Besenbacher is listed by NOON Ventures as Industrial Advisor. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Ashraf Lotfi is listed by NOON Ventures as Industrial Advisor. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Arend van der Weijden is listed by NOON Ventures as Industrial Advisor. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Niels Peder Nielsen is listed by NOON Ventures as Board Member. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Torben Von Lowzow is listed by NOON Ventures as Board Member. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Arve Johan Andresen is listed by NOON Ventures as Board Member. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Christian Dyvig is listed by NOON Ventures as Chairman. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Caspar Høgh is listed by NOON Ventures as General Partner. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

NOON Ventures

Check: The firm does not publish a standard check-size range on its current official website.

Theis Malmborg is listed by NOON Ventures as General Partner. No narrower personal thesis is asserted beyond the firm's published strategy: Concentrate on a small number of proven deep-tech innovations and co-develop them into industry-defining companies with positive climate or environmental impact.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Zosia van Eesteren invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wim Schimmel is listed in a Operational Partner capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wessel van 't Klooster invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Varsha Ram Balapa is listed in a Climate Specialist - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tristan Maguet invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tom Klein Robbenhaar invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Susana Amorim invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephanie Mooij is listed in a Head of Responsible Investment - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephan Wachtveitl invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stefan Luzi invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stacey Vrijhof is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Sonia Hallen invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Silke Kranz invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Senay Sarsik is listed in a Office Manager Frankfurt - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Romy Wiering is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Robert Stein invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rik Maerten is listed in a Junior Fund Controller - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Redmar Koene invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Raphael Arndt invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rafael Natanek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pommeline Korstanje invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pieter van der Meer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pheline Mulitze invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Paulien Schippers is listed in a Finance Manager - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Oksana van Vliet is listed in a Legal & AML/KYC counsel - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Nellie Johnson is listed in a Executive Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Michel Verhoog invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Max Steeman invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Martin von Berg invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marloes Herbrink is listed in a Finance Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marion Pouillard invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Luna van den Brink is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Ludo Suykerbuyk is listed in a General Counsel & Compliance Officer - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Lara Hilgert invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Katharina Mono is listed in a ESG & Impact Analyst - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kate Ebbenhorst is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kasia Lorek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Karthik Bolisetty invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Josephine Bogaerts invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Muijrers invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Heldens invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jelte Goettsch invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jasper van Gorp invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Janke Dittmer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jan Willem Bakker is listed in a Head of Investor Relations / Partner - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Iskander Shadid invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Hugo de Bruin invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Henry Zubaida invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Hein Ploegmakers invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Giel Modderman invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Geoff Pardo invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Edwin de Graaf invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Edward Hanlon invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Dirkjan Beugelsdijk is listed in a CFO - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Christiaan Sap is listed in a Operational Partner capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Forbion

Naarden, Netherlands

Gilde Healthcare

Utrecht, Netherlands

Pillar VC

Boston, Massachusetts

Cambridge Innovation Capital

Cambridge, United Kingdom

The Creator Fund

London, United Kingdom

NLC Health Ventures

Amsterdam, Netherlands

Seventure Partners

Paris, France

Giant Ventures

London, United Kingdom and United States

M Ventures

Amsterdam, Netherlands

Wellington Partners

Munich, Germany

Kurma Partners

Paris, France / Munich, Germany

FoodLabs

Berlin, Germany

Capricorn Partners

Leuven, Belgium

BioGeneration Ventures

Naarden, Netherlands

Hadean Ventures

Oslo, Norway and Stockholm, Sweden

Indaco Venture Partners

Milan, Italy

Uniseed

Australia

Type One Ventures

Malibu, California

Foothill Ventures

Los Altos, California

Fifty Years

San Francisco, California

Newton Biocapital

Brussels, Belgium and Tokyo, Japan

Nucleus Capital

Berlin, Germany

NOON Ventures

Copenhagen, Denmark

Vsquared Ventures

Munich, Germany

Claris Ventures

Turin, Italy

E2MC

Arlington, Virginia

Panakès Partners

Milan, Italy

Clarevia

Madison, Wisconsin

E14 Fund

Cambridge, Massachusetts

Navigare Ventures

Stockholm, Sweden

Uni.Fund

Athens, Greece

Outset Ventures

Auckland, New Zealand

South Central Ventures

Southeast Europe

Civilization Ventures

San Francisco, California

INKEF Capital

Amsterdam, Netherlands

Thuja Capital

Utrecht, Netherlands

ZAKA VC

Bratislava / Prague / London / Silicon Valley

i&i Bio

Prague, Czechia

Hard2beat

Wrocław, Poland

Iron Wolf Capital

Vilnius, Lithuania / Tallinn, Estonia

JumpStart Ventures

Cleveland, Ohio

AUM: $140M+ under management

Unconventional Ventures

Copenhagen, Denmark

V-Bio Ventures

Ghent, Belgium

Vesna VC

Luxembourg; Ljubljana, Slovenia; and Zagreb, Croatia

BSV Ventures

Vilnius, Lithuania

Future Food Fund

Utrecht, Netherlands

Vesalius Biocapital

Luxembourg

Ohio Innovation Fund

Dublin, Ohio

SciFi VC

San Francisco, California

Brunnur Ventures

Reykjavík, Iceland

Cantos Ventures

San Francisco, California

OCCIDENT

Munich, Germany and Zug, Switzerland

Future Ventures

Los Altos, California

Metaplanet

Tallinn, Estonia

Wireframe Ventures

San Francisco, California

INITIATE Ventures

United States

Embark Ventures

Los Angeles, California

First Star Ventures

Cambridge, Massachusetts

Humbition

New York, New York

Smartlink Partners

Warsaw, Poland

Refactor Capital

Burlingame, California